Skip to main content

Table 3 Epidemiology of MRONJ

From: Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review

MRONJ-inducing drugs Prevalence Incidence
Oral bisphosphonates Intravenous bisphosphonates <0.001% (0% to 0.04%) 1.0% to 2.3% for 3-year administration 1.04 to 69 per 100,000 patient-years 0 to 12,222 per 100,000 patient-years
Anti-RANKL antibody Osteoporosis Cancer 1.3% to 3.2% for 3-year administration 0 to 30.2 per 100,000 patient-years 0 to 2,316 per 100,000 patient-years
Angiogenic inhibitors 0.3% to 0.4%
Anti-sclerostin antibody Unknown Unknown
Anti-TNFα antibody
Anti-CD20 antibody
Other monoclonal antibodies
Tyrosine kinase inhibitors
mTOR inhibitors